| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On CNBC's “Mad Money Lightning Round,” Jim Cramer said TORM plc (NASDAQ:TRMD) has a “remarkably high dividend yield. And as long as it has that dividend yield, the stock's going to stay up. But, when things start going bad, and they always do in this business, that yield's going to start going down.”
On July 23, Evercore ISI Group analyst Jonathan Chappell maintained TORM with an Outperform rating, while increasing the price target from $45 to $48.
Cramer recommended buying Trane Technologies plc (NYSE:TT). “Hard to stop a Trane,” he added.
Trane Technologies will report its second-quarter financial results on Wednesday, July 31. Analysts expect the company to report quarterly earnings at $3.08 per share, up from $2.68 per share in the year-ago period. Trane is projected to post quarterly revenue of $5.13 billion compared to $4.7 billion a year ago, according to data from Benzinga Pro.
See Also: Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock ‘Hand Over Fist’
When asked about Axsome Therapeutics, Inc. (NASDAQ:AXSM), he said, “This is central nervous system, CNS. If you can make a breakthrough in CNS, your stock will double. If not, it will just go down. That's a double or nothing stock right there.”
On July 22, Needham analyst Ami Fadia initiated coverage on Axsome Therapeutics with a Buy rating and announced a price target of $130.
The “Mad Money” host said SAP SE (NYSE:SAP) is “incredible” and recommended buying the stock. “I think that SAP is not done going higher,” he added.
On July 22, SAP reported second-quarter earnings of 82 cents per share which missed the analyst consensus estimate of $1.19 per share. Quarterly sales came in at $8.92 billion which missed the analyst consensus estimate of $8.96 billion, representing an 8.81% increase over sales from the same period last year, according to data from Benzinga Pro.
Price Action:
Read Next:
